南非PopART试验:CD4≥500启动早期ART者病毒学结局更优
该前瞻性队列研究在南非PopART试验中纳入1901名启动通用ART的成人,比较不同基线CD4分层者的病毒学结局。基线CD4≥500 cells/µL者至30个月各6个月间隔病毒学抑制率均≥94%,病毒载量升高风险及病毒学失败发生率均低于CD4 200-499 cells/µL者。
要点
- 基线CD4≥500 cells/µL者病毒学抑制率至30个月各间隔均≥94%。
- CD4≥500者病毒载量≥400 copies/mL风险低于200-499者(aRR 0.30)。
- 病毒学失败发生率随基线CD4降低而升高(<200、200-499、≥500分别为7.0、2.0、0.5/100人年)。
核心结论
- 尽管既往存在担忧,基线CD4≥500 cells/µL启动ART者病毒学结局很好,且优于CD4 200-499 cells/µL者。
研究设计与样本
- 前瞻性队列研究,纳入自2014年1月起在南非提供通用ART的机构启动ART的成人,共1901人。
主要发现
- 基线CD4≥500 cells/µL者在至30个月的所有6个月间隔中病毒学抑制(<400 copies/mL)均≥94%。
关键数值与推荐
- 病毒学抑制定义为<400 copies/mL,确认病毒学失败定义为连续2次病毒载量>1000 copies/mL。
临床怎么用
- 支持在CD4≥500 cells/µL时尽早启动ART,不必担心临床状况良好者依从性差或病毒学抑制不佳。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There have been concerns about reduced adherence and human immunodeficiency virus (HIV) virological suppression (VS) among clinically well people initiating antiretroviral therapy (ART) with high pre-ART CD4 cell counts. We compared virological outcomes by pre-ART CD4 count, where universal ART initiation was provided in the HIV Prevention Trials Network 071 (PopART) trial in South Africa prior to routine national and international implementation. METHODS: This prospective cohort study included adults initiating ART at facilities providing universal ART since January 2014. VS (<400 copies/mL), confirmed virological failure (VF) (2 consecutive viral loads >1000 copies/mL), and viral rebound were compared between participants in strata of baseline CD4 cell count. RESULTS: The sample included 1901 participants. VS was ≥94% among participants with baseline CD4 count ≥500 cells/µL at all 6-month intervals to 30 months. The risk of an elevated viral load (≥400 copies/mL) was independently lower among participants with baseline CD4 count ≥500 cells/µL (3.3%) compared to those with CD4 count 200-499 cells/µL (9.2%) between months 18 and 30 (adjusted relative risk, 0.30 [95% confidence interval, .12-.74]; P = .010). The incidence rate of VF was 7.0, 2.0, and 0.5 per 100 person-years among participants with baseline CD4 count <200, 200-499, and ≥500 cells/µL, respectively (P < .0001). VF was independently lower among participants with baseline CD4 count ≥500 cells/µL (adjusted hazard ratio [aHR], 0.23; P = .045) and 3-fold higher among those with baseline CD4 count <200 cells/µL (aHR, 3.49; P < .0001). CONCLUSIONS: Despite previous concerns, participants initiating ART with CD4 counts ≥500 cells/µL had very good virological outcomes, being better than those with CD4 counts 200-499 cells/µL. CLINICAL TRIALS REGISTRATION: NCT01900977.
引用
- Fatti G, Grimwood A, Nachega JB, et al. Better Virological Outcomes Among People Living With Human Immunodeficiency Virus (HIV) Initiating Early Antiretroviral Treatment (CD4 Counts ≥500 Cells/µL) in the HIV Prevention Trials Network 071 (PopART) Trial in South Africa. Clin Infect Dis. 2020. PMID: 30877753. doi:10.1093/cid/ciz214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。